Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
RALEIGH, N.C., Dec. 14, 2017 -- INC Research/inVentiv Health (Nasdaq:INCR), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco. Mr. Macdonald’s presentation is scheduled for Tuesday, January 9, 2018, at 8:00 a.m. PST.
Links to INC/inVentiv’s live presentation and archived audio replay, as well as the presentation materials, will be available via the Company’s Investor Relations website at investor.incresearch.com.
About INC Research/inVentiv Health
INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, our global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information on our Raleigh, N.C.-based company, visit incresearch.com or inventivhealth.com.
| Investor Relations Contact: | Press/Media Contact: | |
| Ronnie Speight | Danielle DeForge | |
| Vice President, Investor Relations | Senior Director, External Communications | |
| +1 919 745 2745 | +1 781 425 2624 | |
| [email protected] | [email protected] |
